XKDCT-086

N/A

Report date: 2024/11/28 11:09:27

Base Information

Drug NameXKDCT-086

Drug Alias NameiPD-1-Claudin18.2-CAR-TXKDCT086XKDCT-086

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionClaudin 18 protein modulators

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaClinical

Originator CompaniesThe Affiliated Hospital Of Qingdao University

China Registration ClassN/A

Develop Information

Active CompaniesThe Affiliated Hospital Of Qingdao University

Inactive CompaniesN/A

Active IndicationsStomach Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A